Literature DB >> 26091088

Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.

Aaron H Rose1, FuKun W Hoffmann, Jared H Hara, Johann Urschitz, Stefan Moisyadi, Peter R Hoffmann, Pietro Bertino.   

Abstract

Adjuvants for DNA vaccination are designed to promote transformation of transgenes into target cells and increase inflammation in the site of injection, with resultant immune cell recruitment. Numerous studies indicated cationic liposomes as effective adjuvants for DNA vaccination due to their ability to promote in vivo transfection and innate immune system activation. Commercial reagents as Adjuplex and in vivo-JetPEI are also intended to facilitate DNA vaccination. Here, we evaluate the adjuvant properties of cationic liposomes, Adjuplex and in vivo-JetPEI compared to injection of DNA without adjuvant. In mice vaccinated with piggyBac pDNA vaccines, we assessed in vivo antigen expression, innate immune responses in draining lymph nodes, and antigen-specific T cell responses in spleens and blood. Surprisingly, vaccination with DNA in PBS emerged as the most efficient in promoting in vivo transfection and consequent antigen expression, while the addition of adjuvant reduced the amount of antigen expressed. On the other hand, we discovered higher numbers of innate immune cells and activated dendritic cells in the lymph nodes of mice injected with adjuvants than those vaccinated in PBS. The analysis of eGFP-specific immune responses revealed that all the different immunizations induced functional antigen-specific T cells in spleens, although only T cells generated by non-adjuvant vaccination and Adjuplex were identified in the blood of vaccinated mice. These results provide insight into the effects of these 3 adjuvants and may facilitate appropriate use off adjuvants by researchers using DNA vaccines in laboratory animals.

Entities:  

Keywords:  Adjuplex; DNA vaccine; JetPEI; adjuvants; cell mediated immunity; innate immunity; liposomes; piggyBac; transposase

Mesh:

Substances:

Year:  2015        PMID: 26091088      PMCID: PMC4635848          DOI: 10.1080/21645515.2015.1047567

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

Review 1.  Genetic adjuvants for DNA vaccines.

Authors:  J Y Scheerlinck
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

2.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

3.  The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering.

Authors:  Harpreet Singh-Jasuja; Allan Thiolat; Matthieu Ribon; Marie-Christophe Boissier; Natacha Bessis; Hans-Georg Rammensee; Patrice Decker
Journal:  Immunobiology       Date:  2012-02-21       Impact factor: 3.144

4.  Helper-independent piggyBac plasmids for gene delivery approaches: strategies for avoiding potential genotoxic effects.

Authors:  Johann Urschitz; Miyuri Kawasumi; Jesse Owens; Kazuto Morozumi; Hideaki Yamashiro; Ilko Stoytchev; Joel Marh; James A Dee; Kris Kawamoto; Craig J Coates; Joseph M Kaminski; Pawel Pelczar; Ryuzo Yanagimachi; Stefan Moisyadi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

5.  Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses.

Authors:  Winni De Haes; Joanna Rejman; Charlotte Pollard; Céline Merlin; Marc Vekemans; Eric Florence; Stefaan C De Smedt; Johan Grooten; Guido Vanham; Stefaan De Koker; Ellen Van Gulck
Journal:  Nanomedicine (Lond)       Date:  2012-08-14       Impact factor: 5.307

Review 6.  Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.

Authors:  George Koob; Martin J Hicks; Sunmee Wee; Jonathan B Rosenberg; Bishnu P De; Stephen M Kaminsky; Amira Moreno; Kim D Janda; Ronald G Crystal
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

7.  Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells.

Authors:  Stephen McCartney; William Vermi; Susan Gilfillan; Marina Cella; Theresa L Murphy; Robert D Schreiber; Kenneth M Murphy; Marco Colonna
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

8.  Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8(+) T cell responses.

Authors:  Pietro Bertino; Johann Urschitz; Fukun W Hoffmann; Bo Ra You; Aaron H Rose; Woo Hyun Park; Stefan Moisyadi; Peter R Hoffmann
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

Review 9.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

10.  Proof of principle for epitope-focused vaccine design.

Authors:  Bruno E Correia; John T Bates; Rebecca J Loomis; Gretchen Baneyx; Chris Carrico; Joseph G Jardine; Peter Rupert; Colin Correnti; Oleksandr Kalyuzhniy; Vinayak Vittal; Mary J Connell; Eric Stevens; Alexandria Schroeter; Man Chen; Skye Macpherson; Andreia M Serra; Yumiko Adachi; Margaret A Holmes; Yuxing Li; Rachel E Klevit; Barney S Graham; Richard T Wyatt; David Baker; Roland K Strong; James E Crowe; Philip R Johnson; William R Schief
Journal:  Nature       Date:  2014-02-05       Impact factor: 49.962

View more
  3 in total

1.  8th vaccine renaissance: A creative nexus for vaccine developers.

Authors:  Heather Johnson; Lenny Moise; Austin Menge; Sarah Beseme; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2015-07-09       Impact factor: 3.452

2.  DNA-Loaded Cationic Liposomes Efficiently Function as a Vaccine against Malarial Proteins.

Authors:  Wesley L Fotoran; Rachele Santangelo; Beatriz N M de Miranda; Darrell J Irvine; Gerhard Wunderlich
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-23       Impact factor: 6.698

Review 3.  Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases.

Authors:  Ziyang Xu; Ami Patel; Nicholas J Tursi; Xizhou Zhu; Kar Muthumani; Daniel W Kulp; David B Weiner
Journal:  Front Med Technol       Date:  2020-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.